Acurx Pharmaceuticals (ACXP) vs InMed Pharmaceuticals (INM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InMed Pharmaceuticals is the larger company by market cap ($7.5 million vs $7.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | INM |
|---|---|---|
| Share price | $1.26 | $1.36 |
| Market cap | $7.00M | $7.47M |
| 1-day change | +0.79% | +2.26% |
| EPS (TTM) | $-2.67 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $2.40 |
| 52-week low | $1.23 | $0.575 |
| Distance from 52-week high | -84.21% | -43.33% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1249.21% | — |
| Average volume | 125.08K | 914.23K |
| Shares outstanding | 5.56M | 5.49M |
| Employees | 4 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About InMed Pharmaceuticals
INM stock →InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ACXP vs INM FAQ
Which is bigger, Acurx Pharmaceuticals or InMed Pharmaceuticals?
InMed Pharmaceuticals (INM) is larger, with a market capitalization of $7.47M compared with $7.00M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and InMed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.